Back to Search
Start Over
Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients.
- Source :
-
International immunopharmacology [Int Immunopharmacol] 2021 Dec; Vol. 101 (Pt B), pp. 108241. Date of Electronic Publication: 2021 Oct 15. - Publication Year :
- 2021
-
Abstract
- Background: IFNβs are known as one of the most promising drugs used for COVID-19 treatment. This study aimed to investigate the effects of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) on COVID-19 inpatients.<br />Methods: In this study, we retrospectively evaluated the clinical treatment outcomes of 100 patients with COVID-19 who received IFN-β 1-a and IFN-β 1-b during their hospitalization period. The rate of discharge from the hospital was considered equal to the clinical improvement and then evaluated as a primary outcome. Moreover, mortality, ICU admission and length of ICU stay, frequency of intubation and use of mechanical ventilation, duration of hospitalization, laboratory factors, and medications were assessed as secondary outcomes.<br />Results: The median discharge time of IFN-β 1a recipients was approximately equal to that of IFN-β 1-b recipients as 9 (5-10) days and 7 (5-11) days, respectively (HR = 2.43, P = 0.75). Mortality rate was also estimated as 10% among IFN-β 1-a recipients and 14% among IFN-β 1-b recipients, which was not statistically significant (p = 0.190). ICU hospitalization rate for the IFN-β 1-a recipients and IFN-β 1-b recipients was 26% and 36%, respectively. In addition, no significant difference was found between these two intervention groups in terms of ICU length of stay (1 (0-2) vs. 1 (0-4.25(, respectively,) P = 0.357). There was no significant difference between the two study groups in terms of frequency of mechanical ventilation and length of hospital stay.<br />Conclusion: There was no significant difference between the two groups in terms of shortening the disease time, clinical improvements and other outcomes.<br /> (Copyright © 2021. Published by Elsevier B.V.)
- Subjects :
- Adenosine Monophosphate analogs & derivatives
Adenosine Monophosphate therapeutic use
Aged
Alanine analogs & derivatives
Alanine therapeutic use
Atazanavir Sulfate therapeutic use
COVID-19 therapy
Dexamethasone therapeutic use
Female
Humans
Immunization, Passive
Inpatients
Intensive Care Units
Male
Middle Aged
Patient Discharge
Respiration, Artificial
Retrospective Studies
Treatment Outcome
Antiviral Agents therapeutic use
Interferon beta-1a therapeutic use
Interferon beta-1b therapeutic use
SARS-CoV-2
COVID-19 Drug Treatment
Subjects
Details
- Language :
- English
- ISSN :
- 1878-1705
- Volume :
- 101
- Issue :
- Pt B
- Database :
- MEDLINE
- Journal :
- International immunopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 34688151
- Full Text :
- https://doi.org/10.1016/j.intimp.2021.108241